<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744625</url>
  </required_header>
  <id_info>
    <org_study_id>2016-1267</org_study_id>
    <nct_id>NCT02744625</nct_id>
  </id_info>
  <brief_title>Physiologic Study of Cerebral Perfusion</brief_title>
  <official_title>Physiologic Study of Cerebral Perfusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to measure cerebral perfusion using MRI in healthy subjects (with and
      without sedation) and in vasopressor-dependent patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global and regional cerebral blood flow</measure>
    <time_frame>Within 15 minutes of intervention initiation</time_frame>
    <description>Cerebral blood flow will be measured by the arterial spin labeling technique (ASL) which provides information expressed in mL/100g/min. Using 3-T MRI technology,we will first acquire T1 images of the brain and sub-regions of interest. Thereafter, ASL sequences will be acquired in contiguous slices. The procedure will be followed on sedation and off sedation for healthy volunteers (in random order) and at mean arterial pressure of 65 mmHg and 75 mmHg (in random order) in patients receiving vasopressor therapy.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Cerebral Perfusion Pressure</condition>
  <condition>Vasopressor Agents</condition>
  <condition>Shock</condition>
  <condition>Magnetic Resonance Imaging (MRI), Functional</condition>
  <arm_group>
    <arm_group_label>Shock lower Mean Arterial Pressure (MAP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vasopressor-dependent treated to lower MAP (65 mmHg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shock higher MAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vasopressor-dependent treated to higher MAP (75 mmHg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy participant awake</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy participant awake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy participant sedated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participant Under light sedation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Higher doses of vasopressor therapy for a MAP of 75 mmHg</intervention_name>
    <arm_group_label>Shock higher MAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lower doses of vasopressor therapy for a MAP of 65 mmHg</intervention_name>
    <arm_group_label>Shock lower Mean Arterial Pressure (MAP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol for light sedation</intervention_name>
    <description>Propofol for light sedation</description>
    <arm_group_label>Shock lower Mean Arterial Pressure (MAP)</arm_group_label>
    <arm_group_label>Shock higher MAP</arm_group_label>
    <arm_group_label>Healthy participant sedated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy Subjects :

          -  Inclusion criteria :

               -  being over 18 years old

          -  Exclusion criterias :

               -  having a positive serum pregnancy test

               -  having a contraindication to MRI

               -  having a contraindication to receive light sedation with propofol

               -  suffering of claustrophobia or of anxiety disorder

        Shock Subjects :

          -  Inclusion criterias :

               -  being over 18 years old

               -  being hospitalized to the medical intensive care unit of the CHUS Fleurimont

               -  being in a stabilized shock state, primarily of distributive etiology

               -  having received an appropriate fluid resuscitation, as judged by the attending
                  physician

          -  Exclusion criterias :

               -  having a different primary etiology of shock than distributive (cardiogenic,
                  hypovolemic, obstructive)

               -  needing vasopressor therapy as the result of extracorporeal circulation

               -  having known cerebral lesions

               -  having an intra-aortic balloon pump

               -  being in a palliative or near end-of-life situation

               -  having a contraindication to MRI

               -  suffering of claustrophobia or of anxiety disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Lamontagne</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Université de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>François Lamontagne</investigator_full_name>
    <investigator_title>Clinician Scientist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

